#TreatTR @azeemlatib @AntonioMangieri @g_lanzillo @PCRonline @Ortega_Paz #EAPCI.

RT @VictorMauriMD: Do the hemodynamic advantages of SEV vs BEV as seen in #SMART translate into superior clinical outcomes in patients with….

RT @PCRonline: 🔥#ACC25 Late-Breaking Trials🔥: Align-AR. 🔗 @CurioJonathan interviews 🎤Raj Makkar about this clinical….

RT @PCRonline: Gearing up for #ACC25 ⌛️ ? So are we!. 🔗 Get the #interventionalcardiology perspective from this yea….

RT @jcecharte: 💥 Recurrent TR at 1 year after successful TEER is linked to poor outcomes @AmJCardio. 🔗 @pedro_cepa….

#TTVR using #EVOQUE by @giuliamasiero3 at #JIMGISE2025 @jimcongress⭐️. 🎯patient w/torrential TR, dilated ann &rheumatic disease,TRISCORE 6.🎯TTVR+predil w/ 28 Cristal Balloon.➡️TTVR becoming an established modality w/ adjunct techniques as w/ other valves, refining the procedure

TAVR + LAAO performed by @Antocol17 @AntonioMangieri at #JIMGISE2025 @jimcongress⭐️. 🎯patient w/ Hb-dropping GI bleeding on DOAC.🎯combined procedure will increase patient comfort.➡️w/ established + standardized procedures available streamlined combination possible

LAAO + M-TEER combo as #livecase from @UniklinikBonn at #JIMGISE2025 @jimcongress ⭐️. 🎯puncture height chosen for good clipping, LAAO will work/follow by steering.🎯TEER first then LAAO.➡️combo safe & doable in reasonable amount of time

#AorticRegurgitation as new #TAVI frontier: @JenaValve #livecase by Matti Adam @UKKoeln at #JIMGISE2025 @jimcongress⭐️. 🎯dedicated device with mechanism clipping to the leaflets.🎯by design commissuraly aligned + not calcium dependent.➡️RCTs vs low/interm risk surgery ongoing

RT @kiadeb87: Exciting session and debate on TAVR controversies: the first cut is the deepest lead by @drnvanmieghem and @AdamGreenbaumMD i….

RT @cescobruno: 🔥🪨Rocking morning session at #JIMGISE2025.📌A case of calcific left main-LAD IVUS guided PCI with orbital from Humanitas.📌A….

RT @jimcongress: 🚨 Get ready for the #JIMGISE2025 sessions on Friday, February 21st!. 👉 Swipe through the carousel to discover what’s in st….

RT @kiadeb87: JIM GISE ROME 2025: evening symposium on TAVR controversies in Room Parallel 1. TAVI in BAV: a look ahead! @Sticchi_Alex @Cur….

Controversies in Mitral Valve Therapy #JIMGISE2025 @jimcongress. 🚨SLDA as remaining challenge in M-TEER.➡️modern M-TEER needs to optimize the procedure for good long-term result.➡️risk of SLDA reduced by stabilising clip, espec when residual MR or prolaps, may need add clip

Update on status & future #TMVR directions by @jgranadacrf #JIMGISE2025 @jimcongress . 🎯devices evolved (single step (sub-)annular or multi step ring+valve w/cath profile⬇️).🎯now safe, reproducible TS procedure . ➡️Next years w/pivotal studies+approval of several device options

M-TEER beyond standard anatomies - F.Bedogni making the case for red zone TEER #JIMGISE2025 @jimcongress. 🎯MR after surg VSD closure.🎯MR after surg chord rupture.🎯MR in small area+ severe MAC. ➡️REPAIR & PRIMARY RCTs will evaluate new M-TEER indications of low/interm risk PMR

RT @jimcongress: Day 2 at #JIMGISE2025 is here!💥. Get ready for an intense day of live cases, symposia, and the exciting Clinical Cases Com….

RT @MrcTsl: Fellow course @jimcongress:. #1 teaching point from #JIMGISE2025:. 🎙️”the use of IVI alone does not necessarily improve patient….

RT @AndreaScotti21: 💥Screening for TTVI: A Call for Innovation to Close the Eligibility Gap.@JACCJournals. 🌐Eligibility for T-TEER vs. TTVR….

Post TAVR PVL + hemolysis treatment via @JACCJournals #JACCR ⬆️.@GilbertTangMD.@mirvatalasnag @BadiwalaMD @JonChrispinMD @KatyuciaDMacedo @ddefariayeh @sarano_maurice @Miho_Fukui_ @theLAdoc @Nishaki1 @ACHDocTMoe @PamelaBMorris @colleenmstack @m_taramasso @SyedZaidMD.

Very educative & nicely illustrated series on #TAVR #PVL + hemolysis by @MonteHeart team in @JACCJournals #JACCCR. 🎯Distinct clinical presentations.➡️Plug based closure .➡️Resolution of hemolysis at f/u. 🔗: